Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?

In chronic lymphocytic leukemia (CLL), there is a growing interest for minimal residual disease (MRD) monitoring, due to the availability of drug combinations capable of unprecedented complete clinical responses. The standardized and most commonly applied methods to assess MRD in CLL are based on fl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Del Giudice, Ilaria, Raponi, Sara, Della Starza, Irene, De Propris, Maria Stefania, Cavalli, Marzia, De Novi, Lucia Anna, Cappelli, Luca Vincenzo, Ilari, Caterina, Cafforio, Luciana, Guarini, Anna, Foà, Robin
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2019
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6727319/
https://ncbi.nlm.nih.gov/pubmed/31555576
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00689
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars